Envoy Medical, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-10-17. It has amended it 3 times. It filed its final prospectus on 2026-02-12, at a public offering price of $0.40 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our Common Stock is listed on The Nasdaq Capital Market under the symbol “COCH” and our Public Warrants are listed on The Nasdaq Capital Market under the symbol “COCHW.” On February 10, 2026, the closing price of our Common Stock was $0.39 per share and the closing price for our Public Warrants was $0.036 per warrant.From the 424B4 filed 2026-02-12
Shares offered
We are offering on a reasonable best efforts basis 47,946,150 shares of our Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), together with Series A-1 warrants to purchase up to 45,000,000 shares of Common Stock (“ Series A-1 Warrants ”), and Series A-2 warrants to purchase up to 75,000,000 shares of Common Stock (“ Series A-2 Warrants ” and collectively with the Series A-1 Warrants, the “ Common Warrants ”).From the 424B4 filed 2026-02-12
Offering price
After giving effect to the shares of our Common Stock to be sold in this offering at a public offering price of $0.40 per share, our as adjusted net tangible book value as of September 30, 2025 would have been $20.2 million, or approximately $0.28 per share of our Common Stock.From the 424B4 filed 2026-02-12
Use of proceeds
Our management will have broad discretion in the application of the net proceeds, including for any of the purposes described in the section of this prospectus entitled “ Use of Proceeds .” We currently intend to use the net proceeds from this offering for working capital and general corporate purposes.From the 424B4 filed 2026-02-12
Net loss or income
We had net losses of $17.2 million and $16.2 million for the nine months ended September 30, 2025 and 2024, respectively, and had an accumulated deficit of $305.7 million and $284.7 million as of September 30, 2025 and December 31, 2024, respectively.From the S-1/A filed 2026-02-06
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-10-17 | Registration statement filed | S-1 |
| 2025-12-01 | Registration statement amended | S-1/A |
| 2025-12-18 | Registration statement filed | S-1 |
| 2026-02-06 | Registration statement amended | S-1/A |
| 2026-02-10 | Registration statement amended | S-1/A |
| 2026-02-12 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-02-12 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Envoy Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.